Melatonin supplementation alters uteroplacental hemodynamics and fetal development in an ovine model of intrauterine growth restriction

Am J Physiol Regul Integr Comp Physiol. 2012 Feb 15;302(4):R454-67. doi: 10.1152/ajpregu.00407.2011. Epub 2011 Nov 30.

Abstract

Using a mid- to late-gestation ovine model of intrauterine growth restriction (IUGR), we examined uteroplacental blood flow and fetal growth during melatonin supplementation as a 2 × 2 factorial design. At day 50 of gestation, 32 ewes were supplemented with 5 mg of melatonin (MEL) or no melatonin (CON) and were allocated to receive 100% [adequate; (ADQ)] or 60% [restricted (RES)] of nutrient requirements until day 130 of gestation. Umbilical artery blood flow was increased from day 60 to day 110 of gestation in MEL vs. CON dams, while umbilical artery blood flow was decreased from day 80 to day 110 of gestation in RES vs. ADQ dams. At day 130 of gestation, uteroplacental hemodynamics, measured under general anesthesia, and fetal growth were evaluated. Uterine artery blood flow was decreased in RES vs. ADQ dams, while melatonin supplementation did not affect uterine artery blood flow. Total placentome weight and placentome number were not different between treatment groups. Fetal weight was decreased by nutrient restriction. Abdominal girth and ponderal index were increased in fetuses from MEL-ADQ dams vs. all other groups. Fetal biparietal distance was decreased in CON-RES vs. CON-ADQ dams, while melatonin supplementation rescued fetal biparietal distance. Fetal kidney length and width were increased by maternal melatonin treatment. Fetal cardiomyocyte area was altered by both maternal melatonin treatment and nutritional plane. In summary, melatonin may negate the consequences of IUGR during specific abnormalities in umbilical blood flow as long as sufficient uterine blood perfusion is maintained during pregnancy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animal Nutritional Physiological Phenomena
  • Animals
  • Antioxidants / therapeutic use*
  • Dietary Supplements
  • Disease Models, Animal
  • Female
  • Fetal Development / drug effects*
  • Fetal Growth Retardation / drug therapy*
  • Kidney / anatomy & histology
  • Kidney / drug effects
  • Maternal Nutritional Physiological Phenomena
  • Melatonin / therapeutic use*
  • Myocytes, Cardiac / drug effects
  • Nutritional Requirements
  • Placental Circulation / drug effects*
  • Placentation
  • Pregnancy
  • Sheep
  • Uterine Artery / drug effects

Substances

  • Antioxidants
  • Melatonin